Biological psoriasis therapies

Adults with severe plaque psoriasis who do not respond to first-line treatments should be offered biological therapies, according to a NICE technology appraisal issued last week. NICE recommends the TNF-alpha blocker etanercept (Enbrel) for the treatment of psoriasis that has not responded to ciclosporin, methotrexate or ultraviolet radiation therapy. If there is no response after 12 weeks, etanercept treatment should be discontinued and treatment with the selective t-cell modulator efalizumab (Raptiva) should be considered.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus